USPTO issues two patents covering Ocata’s immune-modulatory cell technology
The company’s HMC technology introduces a new era of cell therapy for ophthalmic, autoimmune and inflammatory diseases. According to the company, this development allows the generation of a
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.